Encormac

Encormac is a biotechnology company focused on the development of next-generation small molecule inhibitors for the treatment of cancer. The company's primary research centers on targeting Mcl-1, a key member of the Bcl-2 family of proteins that plays a critical role in the survival of various cancer cells and resistance to chemotherapy. By developing highly potent and selective Mcl-1 inhibitors, Encormac aims to provide new therapeutic options for patients with hematologic malignancies and certain solid tumors. The company leverages advanced medicinal chemistry and structural biology to optimize its drug candidates for clinical efficacy and safety.